reports
Euronext completes the acquisition of Admincontrol
Euronext completes the acquisition of Admincontrol Euronext completes the acquisition of Admincontrol The integration of Admincontrol accelerates Euronext Corporate Solutions development in the Nordics and scales up Euronext’s SaaS offering. Amsterdam, Brussels, Dublin, Lisbon, Milan, Oslo and Paris – 13 May 2025 – Euronext, the leading European capital market infrastructure, today announces that it has completed the acquisition of 100% of the shares of Admincontrol for an enterprise value of NOK 4,650 million. The transaction complies with Euronext’s capital allocation policy, with a ROC...
Outcome of the 2025 Shareholders’ Meeting
Outcome of the 2025 Shareholders’ Meeting Press release Regulated information Shareholders expressed strong support for all resolutions, with an approval rate of over 90%. Brussels, May 13, 2025 - 5.45pm CEST Solvay held its Ordinary General Shareholders’ Meeting in Brussels, where all resolutions received strong shareholder support, exceeding 90% of votes, and included: The payment of a gross dividend of €2.43 per share for the year 2024. After deducting the interim dividend of €0.97 gross per share, paid on 22 January 202...
Résultats de l’assemblée générale des actionnaires 2025
Résultats de l’assemblée générale des actionnaires 2025 Communiqué de presse Information réglementée Les actionnaires ont exprimé un fort soutien à toutes les résolutions, avec un taux d'approbation de plus de 90 %. Bruxelles, le 13 mai 2025 - 17h45 CEST Solvay a tenu son assemblée générale des actionnaires à Bruxelles, où toutes les résolutions ont reçu un fort soutien des actionnaires, dépassant 90% des voix, et comprenaient: le versement d’un dividende brut de 2,43 € par action pour l’année 2024. Après déduction de l'acompte sur...
Resultaat van de Algemene Vergadering van Aandeelhouders van 2025
Resultaat van de Algemene Vergadering van Aandeelhouders van 2025 Persbericht Gereglementeerde informatie Aandeelhouders spraken hun sterke steun uit voor alle resoluties, met een goedkeuringspercentage van meer dan 90% Brussel, 13 mei 2025 - 17u45 CEST Solvay hield zijn Algemene Vergadering van Aandeelhouders in Brussel en de aandeelhouders steunden nadrukkelijk alle resoluties, met meer dan 90% van de stemmen, waaronder: De uitbetaling van een brutodividend van €2,43 per aandeel voor het jaar 2024. Na aftrek van het interimdivi...
- Christophe-Raphaël Ganet
- Stephane Beyazian
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
- Christophe-Raphaël Ganet
- Stephane Beyazian
SZG SALZGITTER AG
MRN MERSEN SA
ALCLS CELLECTIS SA
SDF K+S AG
MIL BANK MILLENNIUM SA
SIX2 SIXT SE
COK CANCOM SE
VASTB VASTNED RETAIL BELGIUM NV
KENDR KENDRION NV
TWEKA TKH GROUP N.V. CERT
ALM ALMIRALL SA
DUE DURR AG
BSGR B&S GROUP S.A.
ALFEN ALFEN NV
JEN JENOPTIK AG
HGEA HGEARS AG
IOS IONOS GROUP SE
SPG SPRINGER NATURE AG & CO. KGAA
- Jacob Mekhael
Galapagos 1-1 mgmt. call feedback on re-evaluation of company split
We had a 1-1 call with Galapagos' mgmt. including Henry Gosebruch, newly appointed CEO, and Jérôme Contamine, newly appointed chairman of the board following this morning's announcement regarding the re-evaluation of the proposed company split in favour of strategic alternatives for the cell therapy business. Our takeaway is this new approach leads to a similar outcome intended with the split, but through a smoother path. We summarise our key takeaways in this note.
- ING Helpdesk
Benelux Morning Notes
Alfen: Dead cat bounce? Ayvens: Overhang cure. Belgian telcos: Hey! discontinues €5 offer, OBEL price increases from June 2025. B&S Group: Pulls FY EBITDA guidance in light of tariffs. D'Ieteren: CMD, 1Q25 Preview. Kendrion: Wrestling through difficult macro conditions. NN Group, ASR: Vote on Dutch pension reforms postponed. TKH Group: Not that bad, good progress at Eemshaven. UCB: US Most Favoured Nation initiative back on the agenda. Vastned: Good results, integration ongoing...
- Mahaut Arnaud
- Paul de Froment
- Thomas Mordelle
Alfen: slow Q1 as expected, FY25 guidance cut
Alfen published Q1 2025 figures yesterday. Revenue came in at EUR103.8m (-23% QoQ vs. EUR134.5m in Q4 2024, -11% YoY vs. EUR116.8m in Q1 2024) mainly due to challenging dynamics in EV charging and Energy Storage. This compares with FY25 revenue consensus standing at EUR483m. Q1 numbers were impacte
- Kristof Samoy
Ekopak Ready for a new start
Ekopak announces a €15m capital increase led by Alychlo, alongside major board and management changes. The transaction strengthens governance and liquidity, with Alychlo becoming the dominant shareholder. New projects and reaffirmed credit lines support continued growth under the WaaS model. The transaction, management, and board changes clearly exemplify the intention of reference shareholder Alychlo to re-start with a clean slate and mark a first step in rebuilding investor confidence . We mai...
- Jacob Mekhael
- Kristof Samoy
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Thomas Couvreur
Euronext Trump triggered market rotation benefitting Euronext
Euronext reported strong trading volumes in April, after already elevated volumes in 1Q25. The erratic nature of Trump's policies are clearly benefitting Euronext. Given that we believe this benefit to persist into the next few quarters and years (though not to the same extend as observed in April), we increased our estimates materially, landing on a new TP of €150. Given limited upside following the strong 35% YtD performance, we move from a Buy rating to Accumulate.
- Jacob Mekhael
Galapagos Re-evaluates split in favour of strategic options for cell t...
Galapagos announced that the previously announced company split has been re-evaluated, and instead the company will explore strategic options for the cell therapy business. Henry Gosebruch has been appointed as CEO of Galapagos, replacing Paul Stoffels, effective immediately, and will lead the strategic evaluation process, while also focusing on building a new pipeline through business development. While we find the timing a bit of a surprise, we do note that this outcome could increase the cash...
- Wim Hoste
Solvay Taking a more prudent earnings scenario, lowering target price
After a weak start of the year with a 6% decline in adjusted EBITDA in 1Q25, Solvay now expects FY25 adjusted EBITDA to land in the lower half of the previously given guidance range of € 1.0-1.1bn and we have set our new forecast close to the bottom end of this range. Weak macro conditions, which is mainly visible in soda ash, are for the moment more than offsetting the good progress with efficiency improvement measures. With current EBITDA generation, almost all FCF is absorbed to pay the high ...
- Martijn Den Drijver
Galapagos Announces Strategic Update on Proposed Separation, Executive...
Galapagos Announces Strategic Update on Proposed Separation, Executive Leadership Transition and Board Changes Galapagos to re-evaluate the implementation of the previously announced separation following regulatory and market developments Galapagos to explore all strategic alternatives for its existing businesses, including cell therapy, with a focus on maximizing resources available for transformative business development transactions Mr. Henry Gosebruch appointed by the Galapagos Board of Directors as CEO of Galapagos, effective immediately, succeeding Dr. Paul Stoffels who announced hi...
Galapagos kondigt een strategische update aan over de geplande splitsi...
Galapagos kondigt een strategische update aan over de geplande splitsing, de transitie van het uitvoerend leiderschap, en wijzigingen in de Raad van Bestuur Galapagos heroverweegt uitvoering van eerder aangekondigde splitsing naar aanleiding van ontwikkelingen in regelgeving en de markt Galapagos onderzoekt alle strategische alternatieven voor haar bestaande activiteiten, waaronder celtherapie, met de nadruk op het maximaliseren van de beschikbare middelen voor transformatieve business development transacties De heer Henry Gosebruch is door de Raad van Bestuur van Galapagos benoemd t...
- Jason Kalamboussis
- Reg Watson
- CFA
Euronext/Forging ahead/BUY
Ahead of Euronext's 1Q25 results (to be published after the close on 14 May) we are previewing the company's new reporting structure and updating our forecasts for the strong start to 2025. We also update our valuation to account for the significant re-rating of Euronext's peers. We increase our 12-month target price from €107.8 to €173 and maintain our BUY recommendation.
- ING Helpdesk
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.